zonisamide / Generic mfg.  >>  Phase 4
Welcome,         Profile    Billing    Logout  

22 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zonisamide / Generic mfg.
NCT00047567: Open-label Adjunctive Zonisamide for Bipolar Disorder

Terminated
4
20
US
zonisamide
Elan Pharmaceuticals
Bipolar Disorders
 
07/02
Zonegran, NCT00203450: for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial

Completed
4
20
US
Zonegran, zonisamide, Placebo, placebo pill
Tuscaloosa Research & Education Advancement Corporation, Eisai Inc.
Obesity
03/05
03/06
NCT00215592 / 2005-001982-33: Open Label, Zonegran (Zonisamide) In Partial Onset Seizures

Completed
4
1000
Europe
Zonegran
Eisai Limited
Epilepsy
07/07
 
NCT00259636: Zonisamide for Fibromyalgia & Migraine

Withdrawn
4
0
US
zonisamide
University of Pittsburgh, Eisai Inc.
Fibromyalgia, Migraine
01/08
01/08
NCT00165828 / 2005-000260-57: Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization

Terminated
4
157
Europe
Zonegran
Eisai GmbH
Epilepsy
02/08
02/08
NCT00154076 / 2016-004955-64: A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies

Completed
4
140
RoW
Zonisamide, Zonegran, Topiramate
Eisai Korea Inc.
Epilepsy
08/08
12/08
NCT00713622 / 2007-005313-19: Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate

Completed
4
2
Europe
Zonisamide, Zonegran, Sodium valproate, Epilim
Eisai Limited
Epilepsy
12/08
04/09
NCT01127165 / 2016-004956-32: Low and High Dose Zonisamide in Children as Monotherapy

Completed
4
125
RoW
zonisamide low dose group, zonisamide high dose group
Eisai Korea Inc.
Epilepsy
03/09
07/09
NCT00595556: Zonisamide vs. Placebo in the Treatment of Alcohol Dependence

Completed
4
40
US
zonisamide, Zonegran, Placebo
UConn Health, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Research Resources (NCRR)
Alcoholism, Alcohol Abuse, Alcohol Dependence
05/09
05/09
NCT01127256 / 2016-004957-33: Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation

Completed
4
200
RoW
zonisamide, carbamazepine
Eisai Korea Inc.
Epilepsy
05/09
07/09
NCT00855738: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice

Completed
4
111
NA
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide, Neurontin, Lamictal, Lyrica, Keppra, Topamax, Gabatril, Episen, Zonegran
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Focal Epilepsy
06/09
06/09
NCT00659958: ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs

Completed
4
32
Europe
Zonisamide, Zonegran
Eisai Inc., Eisai Farmacêutica S.A.
Epilepsy
09/09
09/09
NCT01140867 / 2016-004958-14: Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy

Completed
4
121
RoW
zonisamide
Eisai Korea Inc.
Epilepsy
08/10
03/11
NCT01546688 / 2006-002516-10: A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures

Terminated
4
41
Europe
Zonisamide at targeted daily doses of 100-500 mg/day, Placebo administered to match targeted daily doses of 100-500 mg/day
Eisai Limited
Epilepsy
11/10
08/11
NCT01630057 / 2009-010895-64: Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug

Completed
4
200
Europe
Adjunctive Zonisamide, Replacement with Zonisamide
Eisai Inc.
Partial Seizures
06/11
07/12
2012-001884-64: A study of Standard and New Antiepileptic Drugs – SANAD-II.

Ongoing
4
1510
Europe
Sodium Valproate, Lamotrigine, Levetiracetam, Zonisamide, Tablet, Capsule, hard, Lamictal, Keppra, Zonegran
University of Liverpool, The Walton Centre NHS Foundation Trust, National Institute for Health Research (NIHR) Health Technology Assessment Program (HTA)
Epilepsy, Brain disorder, Diseases [C] - Nervous System Diseases [C10]
 
 
2018-000781-10: EFFICACY AND TOLERABILITY OF LOW versus STANDARD DAILY DOSES OF ANTIEPILEPTIC DRUGS IN NEWLY DIAGNOSED, PREVIOUSLY UNTREATED EPILEPSY Efficacia e tollerabilit¿ di basse dosi contro dosi standard dei farmaci antiepilettici in pazienti non trattati di nuova diagnosi.

Not yet recruiting
4
374
Europe
CARBAMAZEPINA, OXCARBAZEPINA, LAMOTRIGINA, LEVETIRACETAM, TOPIRAMATO, ACIDO VALPROICO, GABAPENTIN, ZONISAMIDE, CARBAMAZEPINA BASSA DOSE, OXCARBAZEPINA BASSA DOSE, LAMOTRIGINA BASSA DOSE, LEVETIRACETAM BASSA DOSE, TOPIRAMATO BASSA DOSE, ACIDO VALPROICO BASSA DOSE, GABAPENTIN BASSA DOSE, ZONISAMIDE BASSA DOSE, CARBAMAZEPINA, OXCARBAZEPINA, LAMOTRIGINA, LEVETIRACETAM, TOPIRAMATO, ACIDO VALPROICO, GABAPENTIN, ZONISAMIDE, CARBAMAZEPINA BASSA DOSE, OXCARBAZEPINA BASSA DOSE, LAMOTRIGINA BASSA DOSE, LEVETIRACETAM BASSA DOSE, TOPIRAMATO BASSA DOSE, ACIDO VALPROICO BASSA DOSE, GABAPENTIN BASSA DOSE, ZONISAMIDE BASSA DOSE, Tablet, Capsule, hard, TEGRETOL - 200 MG COMPRESSE A RILASCIO MODIFICATO 30 COMPRESSE, TOLEP - 300 MG COMPRESSE 50 COMPRESSE DIVISIBILI, LAMOTRIGINA DOC - 100 MG COMPRESSE DISPERSIBILI 56 COMPRESSE IN BLISTER ACLAR/PVC/AL, LEVETIRACETAM DOC - 500 MG COMPRESSE RIVESTITE CON FILM 60 COMPRESSE, TOPIRAMATO DOC GENERICI - 100 MG COMPRESSE RIVESTITE CON FILM 60 COMPRESSE IN BLISTER AL/AL, ACIDO VALPROICO SANDOZ - 300 MG COMPRESSE A RILASCIO PROLUNGATO30 COMPRESSE, GABAPENTIN MYLAN GENERICS - 400 MG CAPSULE RIGIDE 500 (5X100) CAPSULE IN BLISTER PVC/ALU CONFEZIONE OSPEDALIERA, ZONEGRAN - 100 MG CAPSULA RIGIDA USO ORALE BLISTER (PVC/ALL) 196 CAPSULE
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, Ministero della Salute, Regione Lombardia
EPILEPSY EPILESSIA, EPILEPSY EPILESSIA, Diseases [C] - Nervous System Diseases [C10]
 
 
KIWE, NCT02205931 / 2013-002195-40: Ketogenic Diet in Infants With Epilepsy

Unknown status
4
160
Europe
Ketogenic diet, Antiepileptic drug therapy, Carbamazepine, Clobazam, Clonazepam, Ethosuximide, Lacosmide, Lamotrigine, Levetiracetam, Nitrazepam, Phenytoin, Rufinamide, Sodium Valproate, Stiripentol, Topiramate, Vigabatrin, Zonisamide
University College, London, Great Ormond Street Hospital for Children NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Alder Hey Children's NHS Foundation Trust, Bristol Royal Hospital for Children, Birmingham Women's and Children's NHS Foundation Trust, The Leeds Teaching Hospitals NHS Trust, Manchester University NHS Foundation Trust, Sheffield Children's NHS Foundation Trust, National Institute for Health Research, United Kingdom, Lancashire Care NHS Foundation Trust, Newcastle-upon-Tyne Hospitals NHS Trust, St George's University Hospitals NHS Foundation Trust
Epilepsy
06/18
06/19
STANDLOW, NCT03689114: Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy

Active, not recruiting
4
374
Europe
Low dose carbamazepine, low carbamazepine, Standard dose carbamazepine, Standard carbamazepine, Low dose levetiracetam, Low levetiracetam, Standard dose levetiracetam, Standard levetiracetam, Low dose valproate, Low valproate, Standard dose valproate, Standard valproate, Low dose zonisamide, Low zonisamide, Standard dose zonisamide, Standard zonisamide, Low dose oxcarbazepine, Low oxcarbazepine, Standard dose oxcarbazepine, Standard oxcarbazepine, Low dose topiramate, Low topiramate, Standard dose topiramate, Standard topiramate, Low dose lamotrigine, Low lamotrigine, Standard dose lamotrigine, Standard lamotrigine, Low dose gabapentin, Low gabapentin, Standard dose gabapentin, Standard gabapentin
Mario Negri Institute for Pharmacological Research, Azienda Ospedaliera San Gerardo di Monza, Ministry of Health, Italy
Epilepsies, Partial
06/24
08/24
ChiCTR2100047311: An observational cohort study on the efficacy and safety of zonisamide as a first add-on treatment in focal epilepsy or focal to bilateral tonic clonic seizures

Recruiting
4
100
 
zonisamide Oral administration, once or twice daily. Titration period: the initial dose was 100 mg/maintenance dose was 200-400 mg/day, increased by 100 mg/day every 2 weeks, 8 to achieve the target dose, and the maintenance dose was 200-400 mg/day. Maintenance Phase: Zonisamide (ZNS) dose stable at 200 to
QiLu Hospital of Shandong University; Jiangxi Qingfeng Pharmaceutical Industry Co., Ltd., Jiangxi Qingfeng Pharmaceutical Co., Ltd.
Epilepsy
 
 
NCT03034538: An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease

Suspended
4
20
US
Zonegran
The Cooper Health System
Parkinson Disease, Parkinsonism, Dyskinesias
12/22
12/22
NCT06534502: Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

Not yet recruiting
4
40
NA
Zonisamide Oral Product, ZONISADE, Zonisamide oral suspension
Azurity Pharmaceuticals
Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy
06/25
06/25

Download Options